Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.

Journal of Virology
Joseph J CarterDenise A Galloway

Abstract

The variable surface loops on human papillomavirus (HPV) virions required for type-specific neutralization by human sera remain poorly defined. To determine which loops are required for neutralization, a series of hybrid virus-like particles (VLPs) were used to adsorb neutralizing activity from HPV type 16 (HPV16)-reactive human sera before being tested in an HPV16 pseudovirion neutralization assay. The hybrid VLPs used were composed of L1 sequences of either HPV16 or HPV31, on which one or two regions were replaced with homologous sequences from the other type. The regions chosen for substitution were the five known loops that form surface epitopes recognized by monoclonal antibodies and two additional variable regions between residues 400 and 450. Pretreatment of human sera, previously found to react to HPV16 VLPs in enzyme-linked immunosorbent assays, with wild-type HPV16 VLPs and hybrid VLPs that retained the neutralizing epitopes reduced or eliminated the ability of sera to inhibit pseudovirus infection in vitro. Surprisingly, substitution of a single loop often ablated the ability of VLPs to adsorb neutralizing antibodies from human sera. However, for all sera tested, multiple surface loops were found to be important for ...Continue Reading

References

Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·J A SuzichR Schlegel
Nov 1, 1996·The Journal of Infectious Diseases·J J CarterD A Galloway
Apr 13, 2000·International Journal of Cancer. Journal International Du Cancer·A P VizcainoD M Parkin
Jan 25, 2003·American Journal of Epidemiology·Rachel L WinerLaura A Koutsky
Jun 17, 2003·Journal of the National Cancer Institute. Monographs·F Xavier Bosch, Silvia de Sanjosé
Jun 17, 2003·Journal of the National Cancer Institute. Monographs·Sue J Goldie

❮ Previous
Next ❯

Citations

Jan 27, 2009·Archives of Virology·Ramon PereiraEdward P Rybicki
Sep 24, 2009·Sexually Transmitted Diseases·Mark SchiffmanNicolas Wentzensen
Dec 21, 2010·Annual Review of Immunology·Ian H FrazerStephen R Mattarollo
Jan 30, 2014·Expert Opinion on Biological Therapy·Suzanne M Garland, Darron R Brown
Dec 5, 2012·Vaccine·John T SchillerSuzanne M Garland
Dec 5, 2012·Vaccine·Margaret StanleyConnie Trimble
Sep 22, 2009·La Presse médicale·Christiane MouginPierre Coursaget
Jun 1, 2010·Journal of Medical Virology·Gilbert CornutUNKNOWN Canadian Women's HIV Study Group
Aug 2, 2011·Progress in Biophysics and Molecular Biology·Harshad JoshiPeter J Ortoleva
Mar 10, 2015·Human Vaccines & Immunotherapeutics·Xiao ZhangQinjian Zhao
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Christine RobertsJoseph Antonello
Jun 1, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Amina I AhmedSimon Beddows
Jul 7, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·E FratiE Tanzi
Sep 14, 2010·Cell Host & Microbe·Patricia M DayJohn T Schiller
Dec 19, 2006·Reviews in Medical Virology·P D Griffiths
Sep 11, 2012·Nature Reviews. Microbiology·John T Schiller, Douglas R Lowy
Apr 4, 2020·Expert Review of Anti-infective Therapy·Ralph-Sydney Mboumba BouassaLaurent Bélec
Jun 6, 2019·Medical Microbiology and Immunology·Monserrat BalandaEugenio Ramírez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.